Ayush Chemopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-06-2024
- Paid Up Capital ₹ 9.80 M
as on 16-06-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.66 Cr
as on 16-06-2024
- Revenue -12.98%
(FY 2023)
- Profit -84.99%
(FY 2023)
- Ebitda -2.33%
(FY 2023)
- Net Worth 1.00%
(FY 2023)
- Total Assets -21.60%
(FY 2023)
About Ayush Chemopharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.80 M.
The company currently has active open charges totaling ₹2.66 Cr.
Mukeshbhai Patel, Alpeshbhai Patel, Jagdish Dolatrai, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100GJ2010PTC061260
- Company No.
061260
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ankleshwar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ayush Chemopharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukeshbhai Patel  | Director | 31-Jul-2012 | Current |
| Alpeshbhai Patel | Director | 31-Jul-2012 | Current |
| Jagdish Dolatrai | Director | 23-Jun-2010 | Current |
| Hareshbhai Patel | Director | 23-Jun-2010 | Current |
Financial Performance of Ayush Chemopharma.
Ayush Chemopharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.98% decrease. The company also saw a substantial fall in profitability, with a 84.99% decrease in profit. The company's net worth moved up by a moderate rise of 1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ayush Chemopharma?
In 2023, Ayush Chemopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Atlas Enviro Solutions LlpActive 1 year 1 monthJagdish Dolatrai and Hareshbhai Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Sep 2014 | ₹1.15 Cr | Open |
Others Creation Date: 05 Sep 2014 | ₹1.51 Cr | Open |
How Many Employees Work at Ayush Chemopharma?
Unlock and access historical data on people associated with Ayush Chemopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ayush Chemopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ayush Chemopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
